Acute disseminated encephalomyelitis (ADEM) is a rare autoimmune disease of the CNS that often after viral infections and mainly affecting children. ADEM is characterized by the onset of multifocal neurologic symptoms, encephalopathy, with brain MRI showing demyelinating abnormalities in the acute phase. Coronavirus disease 2019 (COVID-19) is a novel entity caused by the pandemic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is characterized by influenza-like symptoms, pneumonia, and in severe cases respiratory insufficiency. Many neurologic complications occurring in patients with COVID-19 have been described, and it has been hypothesized that, in some cases, SARS-CoV-2 might exhibit a neurotropic behavior.

Results

We report on a 64-year-old woman with a history of vitiligo, hypertension, and monoclonal gammopathy of undetermined significance who developed an influenza-like syndrome in mid-March 2020 that lasted for 2 weeks. The patient also reported the development of smell and taste deficit that rapidly reached anosmia and ageusia. Starting from April 10, the patient developed bilateral vision impairment associated with sensory deficit on her right leg. She reached the emergency department of our hospital and was referred for ophthalmologic evaluation. Visual acuity was hand motion bilaterally, and relative afferent pupillary defect was detected. Ocular motility and fundus examination were unremarkable, whereas visual field test showed profound defects bilaterally. Neurologic examination, performed on hospitalization, showed mild behavioral abnormalities (irritability), headache, bilateral relative afferent pupil-lary defect, ageusia and anosmia, severe visual loss, right abdominal sensory level, and left-sided lower limb hyper-reflexia with the Babinski sign. The patient underwent a brain and spine MRI scan (figure), with evidence of multiple T1 post-Gd enhancing lesions of the brain, associated with a single spinal cord lesion at the T8 level and with bilateral optic nerve enhancement. A lumbar puncture was performed and showed lymphocytic pleocytosis with 22 cells/mm³ (reference range: 0–5 cells/mm³), mainly represented by CD3⁺CD4⁺ T-cells, with mild hyperproteinorrachia (452 mg/L, reference range: 150–450 mg/L), and identical immunoglobulin G oligoclonal bands were present in the CSF and serum (mirror pattern). PCR for SARS-CoV-2 tested negative on nasal swab and positive on CSF sample. The patient’s serum tested positive for anti-SARS-CoV-2 immunoglobulin G and negative for aquaporin-4 (AQP4) antibody (ab) and antimyelin oligodendrocyte glycoprotein (MOG) ab; the levels of interleukins were not assessed in serum and CSF.

ADEM disease was suspected, and high-dose steroids (IV methylprednisolone 1 g/d for 5 days tapered with oral prednisone 75 mg/d) associated with IV immunoglobulins (2 g/kg in 5 days) were administered. The patient reported significant improvement in visual symptoms and progressive recovery of visual acuity. After 14 days of treatment, vision was 20/30 in the
right eye and 20/25 in the left eye. Visual-evoked potential showed increased latency in both eyes (p100 wave latency: 114 ms right eye, 120 ms left eye, reference: <100 ms). A follow-up brain MRI scan also showed a partial improvement with a reduction in the number of Gd-enhancing lesions. On April 27, the patient was discharged with oral prednisone tapering.

**Discussion**

We report a rare case of an immune-mediated CNS disease that occurs after SARS-CoV-2 infection. Phenotypically, the disease resembled an atypical form of neuromyelitis optica spectrum disorder; however, (1) the hyperacute dynamic of the disease, (2) the presence of multiple, synchronous, enhancing brain lesions, (3) the lack of anti-AQ4 or anti-MOG abs, (4) the absence of longitudinally extended transverse myelitis, and (5) the presence of a viral infection preceding the development of neurologic symptoms do not support this hypothesis, favoring ADEM diagnosis.

Since COVID-19 is currently a pandemic disease, neurologists should be aware that autoimmune neurologic complications involving the CNS might occur and should be promptly recognized and treated to reduce permanent neurologic disability.

**Study funding**

No targeted funding reported.

**Disclosure**

G. Novi: received speaker honoraria from Merck, Novartis, and Roche. T. Rossi: reports no disclosures relevant to the manuscript. Enrico Pedemonte: received speaker honoraria or consultation fees from Biogen and Merck-Serono. L. Saitta: reports no disclosures relevant to the manuscript. C. Rolla: reports no
disclosures relevant to the manuscript. L. Roccatagliata: reports no disclosures relevant to the manuscript. M. Inglese: received honoraria or consultation fees from Roche, Biogen, Merck-Serono, Novartis, and Genzyme and research grants from NIH, NMSS, FISM, and Teva Neuroscience. D. Farinini: reports no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Publication history

Appendix Author

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giovanni Novi, MD</td>
<td>San Martino Hospital, Genova</td>
<td>Major role in the acquisition of data, interpreted the data, design and conceptualized study, analyzed the data, and drafted the manuscript</td>
</tr>
<tr>
<td>Tommaso Rossi, MD</td>
<td>San Martino Hospital, Genova</td>
<td>Major role in the acquisition of data</td>
</tr>
<tr>
<td>Enrico Pedemonte, MD</td>
<td>San Martino Hospital, Genova</td>
<td>Major role in the acquisition of data</td>
</tr>
</tbody>
</table>

Laura Saitta, MD
San Martino Hospital, Genova
Major role in the acquisition of data

Claudia Rolla, MD
San Martino Hospital, Genova
Major role in the acquisition of data

Luca Roccatagliata, MD, PhD
University of Genova, Genova, Italy
Analyzed the data and revised the manuscript for intellectual content

Matilde Inglese, MD, PhD
University of Genova, Genova, Italy
Interpreted the data, design and conceptualized study, analyzed the data, and revised the manuscript for intellectual content

Daniele Farinini, MD
San Martino Hospital, Genova
Revised the manuscript for intellectual content

Appendix (continued)

References
Acute disseminated encephalomyelitis after SARS-CoV-2 infection
Giovanni Novi, Tommaso Rossi, Enrico Pedemonte, et al.
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000797

This information is current as of June 1, 2020
<table>
<thead>
<tr>
<th><strong>Updated Information &amp; Services</strong></th>
<th>including high resolution figures, can be found at: <a href="http://nn.neurology.org/content/7/5/e797.full.html">http://nn.neurology.org/content/7/5/e797.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>References</strong></td>
<td>This article cites 2 articles, 0 of which you can access for free at: <a href="http://nn.neurology.org/content/7/5/e797.full.html#ref-list-1">http://nn.neurology.org/content/7/5/e797.full.html#ref-list-1</a></td>
</tr>
<tr>
<td><strong>Citations</strong></td>
<td>This article has been cited by 12 HighWire-hosted articles: <a href="http://nn.neurology.org/content/7/5/e797.full.html#otherarticles">http://nn.neurology.org/content/7/5/e797.full.html#otherarticles</a></td>
</tr>
<tr>
<td><strong>Subspecialty Collections</strong></td>
<td>This article, along with others on similar topics, appears in the following collection(s): <strong>Acute disseminated encephalomyelitis</strong> <a href="http://nn.neurology.org/cgi/collection/acute_disseminated_encephalomyelitis">http://nn.neurology.org/cgi/collection/acute_disseminated_encephalomyelitis</a> <strong>COVID-19</strong> <a href="http://nn.neurology.org/cgi/collection/covid_19">http://nn.neurology.org/cgi/collection/covid_19</a></td>
</tr>
<tr>
<td><strong>Errata</strong></td>
<td>An erratum has been published regarding this article. Please see next page or: /content/8/1/e949.full.pdf</td>
</tr>
<tr>
<td><strong>Permissions &amp; Licensing</strong></td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td><strong>Reprints</strong></td>
<td>Information about ordering reprints can be found online: <a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>
Acute disseminated encephalomyelitis after SARS-CoV-2 infection

In the Clinical/Scientific Note "Acute disseminated encephalomyelitis after SARS-CoV-2 infection" by Novi et al., there is an error in the opening paragraph. The first sentence should read, "Acute disseminated encephalomyelitis (ADEM) is a rare autoimmune disease of the CNS, that often develops after viral infections and mainly affecting children." The publisher regrets the error.

Reference